BioWorld

April 10, 2006

'Extensive' Bidding War Ends With Pfizer Taking Over Rinat

After an almost year-long respite, Pfizer Inc. is throwing money on the biotech table again, this time entering an agreement to buy privately held Rinat Neuroscience Corp. for an undisclosed sum. (BioWorld Today) Read More

Midwest's Chance To Shine: BIO 2006 Arrives In Chicago

Four Points Of Concern As Biotechnology Grows

Cougar Goes Public Through Reverse Merger, Raises $47M

Biotech Execs Ask For BioShield Reform; Security, Money At Issue

Medarex's Public Offering Gets $112M For R&D, Clinical Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...